{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5967","upperLimit":"0.8227","value":"0.7097"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"Proportion of no Grade 4+ non-hematologic toxicity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Add temozolomide to vincristine/irinotecan cycles.","id":"OG000","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"13 participants were excluded because of ineligibility or insufficient information to assess feasibility.","reportingStatus":"POSTED","timeFrame":"From start to week 26 of therapy","title":"Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment","type":"PRIMARY","unitOfMeasure":"Proportion of Participants"}